Inpharma Weekly

, Volume 1075, Issue 1, pp 9–9 | Cite as

Conflicting results with lubeluzole in stroke

  • Robert Carlson
Newsletter Article


Two international, randomised, double-blind, placebo-controlled, phase III trials of the neuroprotective agent lubeluzole in patients with stroke have generated conflicting outcomes. Compared with placebo, a significant improvement was seen in functional outcome in patients receiving lubeluzole in the US/Canadian Lub-Int-9 trial, but not in the European/Australian Lub-Int-5 trial. The results of the 2 trials, and the possible reasons for the differences seen, were discussed during the American Heart Association’s 22nd Annual Joint Conference on Stroke and Cerebral Circulation [ Anaheim, US; February 1997 ].


Placebo Placebo Group Ischaemic Stroke Placebo Recipient Functional Recovery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1997

Authors and Affiliations

  • Robert Carlson

There are no affiliations available

Personalised recommendations